LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Stock List・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Closed

14.8 -0.6

Buy Sell

Overview

Share price change

24h

Current

Min

14.74

Max

15.49

Key metrics
By Trading Economics
Income	35M 9.5M
Sales	35M 94M
EPS	0.06
Profit margin	10.158
Employees	619
EBITDA	35M 17M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+34.92% upside

Market Stats
By TradingEconomics
Market Cap	-358M 2.3B
Previous open	15.4
Previous close	14.8

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

8.81 / 10.18 Support & Resistance

Adaptive Biotechnologies Corp Chart

Past performance is not a reliable indicator of future results.

Related News

9 Dec 2025, 22:13 UTC

Earnings

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 Dec 2025, 21:40 UTC

Earnings

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 Dec 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 Dec 2025, 16:57 UTC

Major Market Movers

Clear Secure Rises on Medicare Identity Verification Contract

9 Dec 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 Dec 2025, 23:46 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 Dec 2025, 23:45 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 Dec 2025, 23:44 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 Dec 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 Dec 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 Dec 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 Dec 2025, 22:42 UTC

Earnings

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 Dec 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Dec 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 Dec 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9 Dec 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 Dec 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 Dec 2025, 20:26 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 Dec 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 Dec 2025, 19:52 UTC

Earnings

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 Dec 2025, 19:17 UTC

Earnings

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 Dec 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Dec 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 Dec 2025, 17:11 UTC

Earnings

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Comparison

Price change

Adaptive Biotechnologies Corp Forecast

Price Target

By TipRanks

34.92% upside

12 Months Forecast

Average 20.17 USD 34.92%

High 22 USD

Low 18 USD

Based on 7 Wall Street analysts offering 12 month price targets forAdaptive Biotechnologies Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Adaptive Biotechnologies Corp - Dist in the past 3 months.

Technical Score

By Trading Central

8.81 / 10.18Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.